Bioasis Technologies's EBIT is $-3.2M, below the Healthcare sector average of $1.9T.
Get informed when a big investor buys or sells
+ FollowAs of Nov 30, 2022
Trailing 12 months ending Nov 30, 2022
Bioasis Technologies (BIOAF) currently reports a EBIT of $-3.2M as of November 2022. That compares with $-3.8M in the prior-year period — up 15.2% year over year. That is below the Healthcare sector average of $1.9T. Use the charts on this page to explore Bioasis Technologies's EBIT history and peer comparisons.
Bioasis Technologies's EBIT increased from $-3.8M to $-3.2M — a 15.2% year-over-year increase (period ending November 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Bioasis Technologies's EBIT of $-3.2M is lower than the Healthcare sector average of $1.9T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
Bioasis Technologies reported $-3.2M in EBIT as of November 2022. That compares with $-3.8M in the prior-year period — up 15.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current EBIT of $-3.2M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $1.9T. From there, open related valuation or income-statement pages for Bioasis Technologies, and consider following BIOAF for alerts when major investors trade the stock.